Keryx Biopharma (KERX) Reports In-Line Q2 EPS

Keryx Biopharma (NASDAQ: KERX) reported Q2 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.86 million.

"We are making progress on several important milestones across our business, including securing broad reimbursement for Auryxia™ (ferric citrate) that today enables unrestricted access for approximately 65 percent of phosphate binder patients," said Greg Madison, chief executive officer of Keryx. "Our second quarter results show that Auryxia's traction is increasing as we gain reimbursement access. Given that we now have access to the majority of patients and the amount of time required with the dialysis care team to pull through prescriptions, we have decided to add approximately 30 sales representatives to our field sales team. The increase from 60 to approximately 90 representatives, which we expect to complete in the fourth quarter, will allow us to increase our reach and frequency of contact with physicians and the dialysis care team."

Madison continued, "We continue to make progress on two growth opportunities, with the recent CHMP positive opinion in the E.U. for Fexeric® and completion of enrollment in the ongoing Phase 3 label expansion study for Auryxia. These advancements bring us closer to delivering on our goal of building a market leading renal business."

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Optimum Communications gets NYSE non-compliance notice over stock price